Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias Oelke

Showing results (1-10 of 168) with videos related to

Pageof 17
Sort By:
European Urology|February 1, 2012
Re: Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the reduction by dutasteride of prostate cancer events trialMatthias Oelke
Clinical Drug Investigation|February 25, 2015
Latest developments in the assessment and treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: what is clinically relevant?Matthias Oelke
Toxins|July 26, 2024
Strategies for Safe Transurethral Injections of Botulinum Toxin into the Bladder WallMatthias Oelke
BJU International|September 8, 2011
Automatic evaluation of ultrasonography-estimated bladder weight and bladder wall thickness in community-dwelling men with presumably normal bladder functionMatthias Oelke
Neurourology and Urodynamics|May 1, 2010
International Consultation on Incontinence-Research Society (ICI-RS) report on non-invasive urodynamics: the need of standardization of ultrasound bladder and detrusor wall thickness measurements to quantify bladder wall hypertrophyMatthias Oelke
Neurourology and Urodynamics|November 30, 2012
Editorial comment on "Wada N, Kita M, Hashizume K, et al. Urodynamic effects of dutasteride add-on therapy to alpha-adrenergic antagonist for patients with benign prostatic enlargement: prospective pressure-flow study. Neurourol Urodyn 2013;32:1123-7"Matthias Oelke
The Journal of Urology|September 24, 2013
Re: Editorial comment on monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial (Eur Urol 2012; 61: 917-925): S. A. Kaplan J Urol 2013; 189: 1448-1449Matthias Oelke
Neurourology and Urodynamics|April 2, 2022
RE: Joint terminology documents: Quality and a justifiable need, not quantityBernard Haylen, Matthias Oelke
World Journal of Urology|January 12, 2011
Age-stratified normal values for prostate volume, PSA, maximum urinary flow rate, IPSS, and other LUTS/BPH indicators in the German male community-dwelling population aged 50 years or olderRichard Berges, Matthias Oelke
Current Opinion in Urology|December 6, 2008
Positioning invasive versus noninvasive urodynamics in the assessment of bladder outlet obstructionMichiel Arnolds, Matthias Oelke
Pageof 17

Showing results (1-10 of 168) with videos related to

Sort By:
Pageof 17
European Urology|February 1, 2012
Re: Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the reduction by dutasteride of prostate cancer events trialMatthias Oelke
Clinical Drug Investigation|February 25, 2015
Latest developments in the assessment and treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: what is clinically relevant?Matthias Oelke
Toxins|July 26, 2024
Strategies for Safe Transurethral Injections of Botulinum Toxin into the Bladder WallMatthias Oelke
BJU International|September 8, 2011
Automatic evaluation of ultrasonography-estimated bladder weight and bladder wall thickness in community-dwelling men with presumably normal bladder functionMatthias Oelke
Neurourology and Urodynamics|May 1, 2010
International Consultation on Incontinence-Research Society (ICI-RS) report on non-invasive urodynamics: the need of standardization of ultrasound bladder and detrusor wall thickness measurements to quantify bladder wall hypertrophyMatthias Oelke
Neurourology and Urodynamics|November 30, 2012
Editorial comment on "Wada N, Kita M, Hashizume K, et al. Urodynamic effects of dutasteride add-on therapy to alpha-adrenergic antagonist for patients with benign prostatic enlargement: prospective pressure-flow study. Neurourol Urodyn 2013;32:1123-7"Matthias Oelke
The Journal of Urology|September 24, 2013
Re: Editorial comment on monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial (Eur Urol 2012; 61: 917-925): S. A. Kaplan J Urol 2013; 189: 1448-1449Matthias Oelke
Neurourology and Urodynamics|April 2, 2022
RE: Joint terminology documents: Quality and a justifiable need, not quantityBernard Haylen, Matthias Oelke
World Journal of Urology|January 12, 2011
Age-stratified normal values for prostate volume, PSA, maximum urinary flow rate, IPSS, and other LUTS/BPH indicators in the German male community-dwelling population aged 50 years or olderRichard Berges, Matthias Oelke
Current Opinion in Urology|December 6, 2008
Positioning invasive versus noninvasive urodynamics in the assessment of bladder outlet obstructionMichiel Arnolds, Matthias Oelke
Pageof 17